Skip to main content
. 2022 Jun;17(6):835–842. doi: 10.2215/CJN.16171221

Table 3.

Primary and secondary outcomes in the sodium-glucose cotransporter-2 inhibitor or dipeptidyl peptidase-4 inhibitor cohorts

Outcome at 180 d Dipeptidyl Peptidase-4, n=37,449, n (%) Sodium-Glucose Cotransporter-2 Inhibitor, n=38,994, n (%) Weighted Hazard Ratio (95% Confidence Interval)
All fracture 172 (0.5) 170 (0.4) 0.95 (0.79 to 1.13)
Falls 880 (2.4) 897 (2.3) 0.98 (0.91 to 1.05)
Hypotension 40 (0.1) 41 (0.1) 0.98 (0.65 to 1.47)
Hypoglycemia 81 (0.2) 77 (0.2) 0.91 (0.68 to 1.22)